This week, the FDA is due to decide on four therapeutic applications, including one for Huntington’s disease and two for ultra-rare diseases.

The first half of 2023 saw the first approvals of therapies for a genetic subset of ALS and a pair of rare neurological disorders, Rett syndrome and Friedreich’s ataxia—and the regulator has several decisions for rare and orphan diseases on the docket in the second half of the year.